Market Place
Sourcing Support
Novo Holdings, OrbiMed, Jeito lead $181M fundraise for ADC biotech
12 Nov 2024 //
FIERCE BIOTECH
Novo Holdings Co-Leads $181.4M Series D in Alentis for ADCs
12 Nov 2024 //
PR NEWSWIRE
Alentis Therapeutics Raises $181.4M for Anti-Claudin-1 ADCs
12 Nov 2024 //
BUSINESSWIRE
Alentis Gets FDA IND Clearance For Squamous Cancer Treatment
02 Oct 2024 //
BUSINESSWIRE
Alentis Appoints Jonathan Freve CFO
03 Sep 2024 //
BUSINESSWIRE
Alentis Gets FDA Orphan Drug Status For IPF Candidate Lixudebart
29 May 2024 //
BUSINESSWIRE
Alentis Appoints Alberto Toso Chief Scientific Officer
29 Apr 2024 //
BUSINESSWIRE
William Pao Joins Alentis Therapeutics as Independent Board Member
08 Jan 2024 //
BUSINESSWIRE
Alentis Therapeutics Expands Leadership Team
06 Dec 2023 //
BUSINESSWIRE
Alentis Doses Progressive Glomerulonephritis Patient in Ph 2 Trial of Lixudebart
05 Dec 2023 //
BUSINESSWIRE
Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04
16 Nov 2023 //
BUSINESSWIRE
Alentis Therapeutics Appoints Lung Experts Professors Tony Mok
05 Oct 2023 //
BUSINESSWIRE
Alentis Therapeutics to Present at the (ERS) International Congress
29 Aug 2023 //
BUSINESSWIRE
Alentis Therapeutics Receives FDA Fast Track Designation for ALE.C04
24 Aug 2023 //
BUSINESSWIRE
Alentis Therapeutics Appoints Luca Santarelli as Chairperson
29 Jun 2023 //
BUSINESSWIRE
Alentis Therapeutics Reports Positive Topline Results From Phase 1
26 Apr 2023 //
BUSINESSWIRE
Alentis secures $105M series C for anti-fibrotic ambitions
13 Apr 2023 //
FIERCE BIOTECH
Alentis Therapeutics Closes $105 Million Series C Funding
13 Apr 2023 //
BUSINESSWIRE
Positive Results from Single Ascending Dose PI of ALE.F02 Targeting Claudin-1
09 Jan 2023 //
BUSINESSWIRE
Alentis Therapeutics Appoints Dr. Andrea Pellacani as Chief Medical Officer
03 May 2022 //
BUSINESSWIRE
Alentis Starts First-in-Human Clinical Trial for Liver and Kidney Fibrosis
04 Jan 2022 //
BUSINESSWIRE
Alentis Appoints Santarelli to Board of Directors, Tordjman as Chairperson
08 Nov 2021 //
BUSINESSWIRE
Alentis Therapeutics Raises $ 67 Million in Series B Funding
15 Jun 2021 //
BUSINESSWIRE
Alentis Therapeutics Raises USD 67 Million in Series B Financing
15 Jun 2021 //
BUSINESSWIRE
Alentis nabs $67M to enter clinic by year-end for anti-fibrotic
14 Jun 2021 //
FIERCEBIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.